Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Curvebeam AI Ltd. ( (AU:CVB) ) just unveiled an update.
CurveBeam AI Limited announced the release of certain securities from escrow restrictions, effective August 22, 2025. This release includes a significant number of shares and options, with 89% of the shares being held by directors, their related parties, and senior leaders. The removal of these restrictions may impact the company’s stock liquidity and market dynamics, potentially affecting stakeholders and investors.
The most recent analyst rating on (AU:CVB) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited develops, manufactures, and sells specialized medical imaging CT scanners, along with AI SaaS-based clinical assessment solutions. These products support medical practitioners in managing musculoskeletal conditions. The company’s flagship product, HiRise™, offers both weight-bearing and traditional CT scans, providing significant advantages over traditional CT or MRI devices. CurveBeam AI operates with over 70 employees, with its corporate office located in Melbourne, Australia, and its global operations headquarters in Hatfield, Pennsylvania, USA.
Average Trading Volume: 199,465
Technical Sentiment Signal: Buy
Current Market Cap: A$44.88M
Find detailed analytics on CVB stock on TipRanks’ Stock Analysis page.